News Archive 2006
Innocoll Announces a Distribution Agreement in the Russian Federation for CollaRx Gentamicin Surgical Implant
ASHBURN, Va., Mar 30 /PRNewswire/ – Innocoll, Inc. announced its sales and marketing subsidiary, Innocoll Pharmaceuticals Ltd., has recently signed a distribution agreement for its CollaRx GENTAMICIN SURGICAL IMPLANT in the Russian Federation. The product is indicated for the treatment and prevention of post-operative acquired infection. Innocoll, Inc. acquired the product rights from Essex Chemis AG, an affiliated company of Schering-Plough Corporation (NYSE: SGP) and has since assumed all sales, marketing and distribution activities for the product. Dr. Michael Myers, President and CEO of Innocoll, Inc., stated, "The Russian Federation, with a population in excess of 140 million and a rapidly growing economy, has the potential to become an extremely important market for us. This is a further step in achieving a global distribution network for both our current and pipeline products.” The product was developed using Innocoll's proprietary collagen-based technology, CollaRx™, and has been approved in over 50 countries. It is marketed under the following different trade names (COLLATAMP® G, COLLATAMP® EG, SULMYCIN® IMPLANT, GARAMYCIN® SCHWAMM, DURACOL®, DURACOLL®, GENTACOL®, GENTACOLL®, GARACOL®, GARACOLL®, CRONOCOL® in Europe, Central and South America, Middle East, Africa and Asia. About Gentamicin Surgical Implant GENTAMICIN SURGICAL IMPLANT is a biodegradable leave-behind implant impregnated with the broad spectrum aminoglycoside antibiotic, gentamicin, and is indicated as an adjunct to systemic antibiotic therapy for the treatment and prevention of post-surgical acquired infection in both hard and soft tissues. It is based on Innocoll's CollaRx™ technology, a proprietary collagen-based system which locally delivers a wide variety of drug products, and can be formulated for implantable or topical application as a lyophilized sponge or as a cast film. About Innocoll, Inc. Innocoll is a privately held, fully integrated, global, hospital specialty pharmaceutical company specializing in surgical and dermatological products. It develops and markets internationally a range of medical products using its proprietary collagen-based technologies, CollaRx™ and LiquiColl®. Innocoll, Inc. acquired the product rights for Collatamp G from Essex Chemis AG, an affiliated company of Schering-Plough Corporation (NYSE: SGP) and has since assumed all sales, marketing and distribution activities for the product. For more information, please visit www.innocoll.com. For product or pipeline information, please visit www.innocoll-pharma.com. Contact: Michelle Cox, Marketing Manager Innocoll Pharmaceuticals +353 (0)90 648 6282 or [email protected]